Upstream Bio (UPB) Change in Accured Expenses (2023 - 2026)

Upstream Bio's Change in Accured Expenses history runs 4 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 166.4% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $7.1 million, a 1201.65% increase from a year earlier, with the FY2025 full-year figure at $4.0 million, up 165.48% from the prior year.
• Change in Accured Expenses retreated to $1.2 million in Q1 2026 per UPB's latest filing, from $2.8 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $3.5 million in Q2 2025 and bottomed at -$1.9 million in Q1 2025.
• The 4-year median for Change in Accured Expenses is $510500.0 (2023), against an average of $739400.0.
• Biggest YoY gain for Change in Accured Expenses was 822.77% in 2025; the steepest drop was 285.71% in 2025.
• Year by year, Change in Accured Expenses stood at $639000.0 in 2023, then surged by 174.65% to $1.8 million in 2024, then surged by 60.74% to $2.8 million in 2025, then sank by 56.43% to $1.2 million in 2026.
• Per Business Quant, the three latest UPB Change in Accured Expenses figures stand at $1.2 million (Q1 2026), $2.8 million (Q4 2025), and -$481000.0 (Q3 2025).